No Data
Stifel Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Raises Target Price to $30
Stifel Nicolaus Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)
JPMorgan Adjusts Price Target on Nurix Therapeutics to $34 From $31, Maintains Overweight Rating
Nurix Therapeutics Analyst Ratings
Nurix Therapeutics Is Maintained at Overweight by Barclays
Express News | Nurix Therapeutics Inc. : Morgan Stanley Raises Target Price to $15.00 From $14.00